MD SB608

Requires Maryland Medicaid, health insurers, nonprofit health service plans, and HMOs to cover single-gene and multigene pharmacogenomic testing beginning July 1, 2027

Coverage applies when a treating provider orders testing for patients diagnosed with depression or anxiety who are being considered for medication changes, dose adjustments, or augmentation involving drugs with known gene-drug interactions

Limits prior authorization requirements by mandating minimum necessary documentation, allowing sufficient time for submission after specimen collection, and permitting either treating providers or laboratories to submit requests

Establishes penalties of up to $10,000 per instance of noncompliance plus $1,000 per day for ongoing violations after notification, with corrective action plan requirements within 30 days

Requires the Insurance Commissioner and Department of Health to conduct periodic compliance audits and establish processes for patients, prescribers, and laboratories to report noncompliance